Shares in a clinical stage drug development have more than doubled in value after it revealed a $160.5m deal.
Evgen Pharma, which is listed on AIM and has bases in Liverpool and Wimslow, has licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla SA.
The Swiss company specialises in the identification of specific phenotypes of autism spectrum disorder (ASD).